Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences Inc. closed $4.71 below its 52-week high ($87.87), which the company achieved on January 19th.

Gilead Sciences has been looking for a win for Trodelvy after two ... argued that the new findings from cohort C and D ...

Gilead Sciences Inc.’s twice-yearly HIV prevention shot prevented almost all HIV cases in a large trial in men and transgender people, a result that will allow the company to file for approval by end ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...

NORTHAMPTON, MA / ACCESSWIRE / September 10, 2024 / This year, we're among 42 organizations being recognized by Seramount as ...